RecruitingPhase 4NCT07389590

Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

A Pilot Study of Ublituximab in People With MS Experiencing Wearing Off Phenomena While Receiving Treatment With Ocrelizumab

Sponsor

Johns Hopkins University

Enrollment

50 participants

Start Date

Feb 10, 2026

Study Type

INTERVENTIONAL

Conditions

Multiple Sclerosis

Summary

The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ocrelizumab and a drug called Ublituximab for people with multiple sclerosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGUblituximab

Ublituzimab will be administered via IV infusion as specified throughout the study period.

DRUGOcrelizumab

Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.

Locations(1)

Johns Hopkins University

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07389590

Related Trials

Single Arm Trial Identifying Barriers and Facilitators to Mindfulness Practice

NCT075732411 location

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT0622020135 locations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients

NCT070855071 location

Optical Coherence Tomography in Neurological Practice: Utility and Applicability Across Neurological Diseases (OCt.IN.N)

NCT077207651 location

A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)

NCT064337651 location